欢迎使用我们的服务！
限时优惠，立即购买享受折扣
24小时客服在线，随时为您服务
优质产品，值得信赖

印度仿制药专卖店
登录
顶 置

文章列表

Aurobindo Receives FDA Approval for Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg

2026-10-02
Revision of the Guidance document Authorisation Biosimilar

2026-10-02
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

2026-10-02
AI, Advanced Computing Project Intended To Modernize US Clinical Trials

2026-10-01
EU Aligns Safety Reporting For Combined Drug-IVD/Device Studies, But Double Reporting Persists

2026-10-01
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®

2026-10-01
How Aspen’s Priyen Naidu drives a human-centred approach to technology

2026-10-01
Australia Sets Five-Year Transition To New Medicines Labeling Standards

2026-10-01
Sun Pharma and LIB Therapeutics announce global licensing agreement for Lerodalcibep

2026-09-30
Frank, in-depth discussion as Belgium and WHO map ahead priorities for collaboration

2026-09-30
Aurobindo Receives FDA Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%

2026-09-30
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026

2026-09-30